CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01024998
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:49.518622+00:00
Published At: 2018-08-22T00:00:00+00:00
Record Updated At: 2018-08-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Macular Degeneration", "Age-Related Maculopathies", "Age-Related Maculopathy", "Maculopathies, Age-Related", "Maculopathy, Age-Related", "Retinal Degeneration", "Retinal Neovascularization", "Gene Therapy", "Therapy, Gene", "Eye Diseases"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2018-08-22"
protocolSection.identificationModule.nctId: "NCT01024998"
protocolSection.identificationModule.officialTitle: "A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.